Article

U.S. clinical trial investigating efficacy of presbyopia treatment approach

Overland Park, KS?An FDA clinical trial evaluating the efficacy and safety of an intracorneal inlay (AcuFocus, Irvine, CA) for the treatment of presbyopia is under way, according to Daniel S. Durrie, MD.

The device is based on the use of small-aperture optics to increase depth of focus. It is doughnut-shaped, ultrathin (approximately 10 μm thick), and constructed of an opaque biocompatible polymer that contains microperforations to permit nutrient flow.

"This device is approaching presbyopia treatment with a new principle that involves changing the optics of the eye instead of the power," Dr. Durrie said.

"The U.S. trial is designed to study efficacy and safety of the corneal inlay in exhaustive detail and is including multiple parameters of quality of vision," he continued. "When it is completed, we will know how well this device works in a large number of patients."

Preliminary results

Speaking at the refractive subspecialty day meeting sponsored by the International Society of Refractive Surgery of the American Academy of Ophthalmology, Dr. Durrie presented preliminary results from a multinational study of the corneal inlay conducted at eight sites in three countries outside of the United States. That trial involved 57 patients with a mean age of 50 years (range, 45 to 60) who were emmetropic (natural or post-LASIK) and received the implant in the non-dominant eye. With follow-up available for up to 9 months in some patients, results showed mean distance uncorrected visual acuity (UCVA) was unchanged while there were improvements in both mean near and intermediate UCVA that appeared to increase over time.

"There might be some cortical adaptation involved with this approach as there is with monovision or perhaps vision improves over time in association with postoperative healing. Those and many other questions remain to be answered," he said.

Dr. Durrie also presented a simple experiment designed by Jack T. Holladay, MD, of Houston, that demonstrates the principles of small-aperture optics for improving depth of focus. Working in his backyard, Dr. Holladay placed a series of eye charts on sticks at different distances and determined how many were legible when the camera focus and f-stop were changed. When the f-stop was set to simulate a 4-mm pupil and the camera focused at 20 feet, four charts were in focus. However, as the focus was brought in closer, first to 12 feet and then 8 feet, the number of charts able to be seen clearly decreased to three and then to two. In contrast, when the f-stop was changed to simulate a 1.6mm pupil, 10 charts could be read when the camera was focused at 20 feet, and the number of charts legible increased as the focus was brought in closer.

Other investigators participating in the U.S. trial of the corneal inlay include Richard L. Lindstrom, MD; Vance M. Thompson, MD; George O. Waring III, MD; Perry S. Binder, MD; Dr. Holladay; and Jay McDonald, MD.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.